Bone Health and Denosumab Discontinuation in Oncology Populations

Managing bone health after denosumab cessation is a commonly encountered challenge. Although the “rebound phenomenon” is generally recognized by endocrinologists in the context of osteoporosis, it is not as widely understood in the context of bone metastases and cancer. This commentary reviews the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheung, Yee-Ming Melody, Morgans, Alicia, Hamnvik, Ole-Petter Riksfjord
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732234/
https://www.ncbi.nlm.nih.gov/pubmed/36250799
http://dx.doi.org/10.1093/oncolo/oyac213
_version_ 1784846081537867776
author Cheung, Yee-Ming Melody
Morgans, Alicia
Hamnvik, Ole-Petter Riksfjord
author_facet Cheung, Yee-Ming Melody
Morgans, Alicia
Hamnvik, Ole-Petter Riksfjord
author_sort Cheung, Yee-Ming Melody
collection PubMed
description Managing bone health after denosumab cessation is a commonly encountered challenge. Although the “rebound phenomenon” is generally recognized by endocrinologists in the context of osteoporosis, it is not as widely understood in the context of bone metastases and cancer. This commentary reviews the evidence on the efficacy and safety of various bone health agents in mitigating the “rebound phenomenon” in cancer populations.
format Online
Article
Text
id pubmed-9732234
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-97322342022-12-13 Bone Health and Denosumab Discontinuation in Oncology Populations Cheung, Yee-Ming Melody Morgans, Alicia Hamnvik, Ole-Petter Riksfjord Oncologist Commentary Managing bone health after denosumab cessation is a commonly encountered challenge. Although the “rebound phenomenon” is generally recognized by endocrinologists in the context of osteoporosis, it is not as widely understood in the context of bone metastases and cancer. This commentary reviews the evidence on the efficacy and safety of various bone health agents in mitigating the “rebound phenomenon” in cancer populations. Oxford University Press 2022-10-17 /pmc/articles/PMC9732234/ /pubmed/36250799 http://dx.doi.org/10.1093/oncolo/oyac213 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Cheung, Yee-Ming Melody
Morgans, Alicia
Hamnvik, Ole-Petter Riksfjord
Bone Health and Denosumab Discontinuation in Oncology Populations
title Bone Health and Denosumab Discontinuation in Oncology Populations
title_full Bone Health and Denosumab Discontinuation in Oncology Populations
title_fullStr Bone Health and Denosumab Discontinuation in Oncology Populations
title_full_unstemmed Bone Health and Denosumab Discontinuation in Oncology Populations
title_short Bone Health and Denosumab Discontinuation in Oncology Populations
title_sort bone health and denosumab discontinuation in oncology populations
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732234/
https://www.ncbi.nlm.nih.gov/pubmed/36250799
http://dx.doi.org/10.1093/oncolo/oyac213
work_keys_str_mv AT cheungyeemingmelody bonehealthanddenosumabdiscontinuationinoncologypopulations
AT morgansalicia bonehealthanddenosumabdiscontinuationinoncologypopulations
AT hamnvikolepetterriksfjord bonehealthanddenosumabdiscontinuationinoncologypopulations

Ejemplares similares